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ABSTRACT:
  Background:  Metronomic  chemotherapy  (MC)  is  defined  as 
the frequent administration of chemotherapy at doses below the 
maximal tolerated dose and with no prolonged drug-free break. MC 
is  gaining  interest  as  an  alternative  strategy  to  fight  resistant  cancer.
  Objective: to assess the safety of 4 drug MC regimen in 
pediatric patients with refractory or relapsing various tumors types.
  Setting: From November 2008 to December 2010, in three academic 
pediatric oncology centers, 16 children (median age 12 years old; range 5.5-20) 
were included in this pilot study. This treatment was proposed to children with 
refractory disease for whom no further effective treatments were available. Most 
frequent diagnosis were medulloblastoma/cerebral PNET (5) osteosarcoma (5), 
and one case each of nephroblastoma, high grade glioma, Hodgkin lymphoma, 
rhabdomyosarcoma, neuroblastoma and kidney rhabdoid tumour. The MC 
regimen consisted in cycles of 56 days (8 weeks) with weekly vinblastine 3 mg/
m² (week 1-7), daily cyclophosphamide 30 mg/m² (days 1-21), and twice weekly 
methotrexate 10 mg/m² (days 21-42), and daily celecoxib 100 mg to 400 mg twice 
daily (days1-56) followed by a 2-weeks chemotherapy break. Adverse events 
were determined through laboratory analysis and investigator observations.
  Results: One objective response was observed in a patient with 
Hodgkin lymphoma, and 4 patients experienced disease stabilization and 
continued their treatment for 3 cycles (24 weeks) or more. At last follow-up, 7 
patients (43%) are alive including 1 still undergoing treatment. During the 
overall 36 cycles of treatments received by patients, 4 grade IV toxicities and 
24 grade III toxicities were observed in 11 cycles in only 10 different patients. 
  Conclusion: The metronomic regimen we report here was well 
tolerated and associated with disease stabilization. This regimen is 
currently being evaluated in a national multicenter phase II study.
INTRODUCTION
Metronomic chemotherapy (MC) is defined as the 
frequent administration of chemotherapy drugs at doses 
below the single maximal tolerated dose and with no 
prolonged drug-free breaks [1]. MC has been reported Oncotarget 2011; 2:  960 - 965 961 www.impactjournals.com/oncotarget
to  significantly  reduce  adverse  events  (AEs)  usually 
associated  with  chemotherapy.  Although  clinical  data 
of MC in pediatric oncology remains sparse [1, 2], this 
approach may be well suited and represents a genuine 
alternative solution for children with poor prognosis or 
refractory disease [3, 4], potentially as a maintenance 
therapy following multimodal treatment [5]. Furthermore, 
its low cost and limited toxicity make MC a very attractive 
therapeutic option in low- and middle-income countries 
[6, 7].
Here,  we  aimed  at  developing  a  new  multidrug 
metronomic protocol for children, integrating the different 
mechanisms of action of MC. Indeed, although MC had 
initially been considered to be an anti-angiogenic therapy 
[8], recent findings have highlighted new effects, which 
all likely contribute to treatment efficacy [1]. These effects 
include the stimulation of the anticancer properties of the 
immune system, re-induction of tumor dormancy as well 
as potential direct effects against cancer cells [1, 9]. 
The potential of etoposide and temozolomide used 
in a metronomic fashion has already been reported [3, 
4,  5,  10].  However,  since  potential  mutagenic  effects, 
including myelodysplasia and secondary leukemias, were 
reported with these agents when administered at more 
conventional dosing [11, 12], they were not included in this 
study. Instead, we designed a metronomic regimen relying 
mainly on oral medications and used a continuous low-
dose methotrexate (MTX) / low-dose cyclophosphamide 
backbone published in 2002 by Colleoni et al. [13]. 
Lower doses of cyclophosphamide were used to avoid 
high hematologic toxicities since cyclophosphomide was 
combined with others anticancer agents. Vinblastine, 
which had already been included in metronomic protocols 
[14, 15], was also added to our protocol. This drug only 
adds little hematological toxicity at the dosage of 3mg/
m² and microtubule-targeting agents are known to be the 
most  potent  Anti-angiogenic  chemotherapeutics  so  far 
[16,17] and bring potential beneficial immunologic effect 
[18]. Lastly, celecoxib has been added as a 4th agent in this 
metronomic combination. Celecoxib has been part of most 
pediatric metronomic regimen [3, 4, 5, 10, 14] as it adds 
potential anti-angiogenic effect and tumor sensitization 
to chemotherapy [19] and very limited toxicity. Here, we 
report of a pilot study of a 4 drug metronomic regimen in 
children with relapsing, refractory solid tumors.
PATIENTS AND PROTOCOL
This  pilot  study  evaluated  the  use  of  MC  with 
cycles  consisting  of  weekly  intravenous  vinblastine 
3 mg/m2 (week 1 to 6 (later changed to 7 see below)), 
daily oral cyclophosphamide 30 mg/m2 (days 1-21), twice 
weekly oral MTX 15 mg/m² (then lowered to 10 mg/m² 
see below) (days 21-42), and twice daily oral celecoxib 
100-400 mg (days 1-42), followed by a 2-week therapy 
break (celecoxib was then kept during the break see 
below). All families gave consent before enrollment of 
the patients in the study. This treatment was proposed to 
children, aged from 3 to 21 years old, with refractory or 
relapsing cancer following treatment protocols available 
in our institutions, or to patients who were not eligible 
for phase I or II trials. All patients with an uncontrolled 
concurrent illness, active infection or unable to swallow 
oral medication were excluded from the study. Adverse 
events (AEs) were determined through laboratory analyses 
and investigator observations and grade using the NCI-
CTC 3.0 criteria. Treatment was terminated upon tumor 
progression, following physician’s decision, according 
to parent’s will or due to unacceptable toxicity. Tumor 
size  was  evaluated  using  bidimensional  measurement. 
Disease  status  evaluated  using  WHO  response  criteria 
Vinblastine  3 mg/m²/week IV 7 weeks
Cyclophophamide 30 mg/m2/day PO for 3 weeks
Methotrexate 10mg/m² 2X/week PO  for 3 weeks
W1 W2 W3 W4 W5 W6 W7 W8
Celecoxib 100-200-400 mg/x2/day PO for 8 weeks
(<20 kg BW, 20-50 kg, > 50 kg, respectively)
W9
Figure 1: Metronomic 4 drugs regimenOncotarget 2011; 2:  960 - 965 962 www.impactjournals.com/oncotarget
(progressive disease: 25% increase, stable disease: neither 
partial response nor PD criteria met, partial response: at 
least 50% decrease and complete response: disappearance 
of all known lesion(s)).
From November 2008 to December 2010, 16 patients 
were included in this study, with a median age of 12 years 
old (5.5-20 years). There were 11 boys and 5 girls. Details 
of the study population and outcomes are reported in table 
1.
The  treatment  plan  was  slightly  modified  after 
treatment of the first 3 patients upon toxicity and clinical 
outcome.  Thus,  and  following  disease  progression 
-suggesting active neo-angiogenesis during chemotherapy 
break-, it was decided to continue celecoxib administration 
between two cycles. A seventh vinblastine administration 
was  also  added  on  day  42.  Then,  as  oral  mucositis 
occurred during the second part of the cycle during which 
patients were taking oral methotrexate and celecoxib, 
methotrexate dosage was diminished from 15 mg/m² to 
10 mg/m². Overall, 10 out of the 16 patients received the 
last implemented version of the regimen.
RESULTS
At  the  end  of  the  observation  period,  the  mean 
duration of treatment was 17 +/- 14 weeks with 1 patient 
still on treatment. 7 out of 16 patients are alive with a 
mean follow-up of 28 +/- 15 weeks. Mean washout period 
was 5.6 +/- 7 weeks. The best response observed was one 
objective response in a child with Hodgkin disease who 
received a modified version of the protocol. Four disease 
stabilizations (25%) that lasted 24 weeks or more were 
also observed. All these patients received the implemented 
version of the regimen. Besides, rapid tumor progression 
was  noted  in  4  patients  (25%)  who  did  not  complete 
the  first  cycle  of  treatment.  When  comparing  time  to 
progression  (TTP)  while  receiving  the  experimental 
metronomic regimen with TTP during the previous line 
of treatment [20,21], we found that TTP obtained with the 
experimental MC was longer in 8 patients (50%) (see table 
1). However, overall there was no statistically significant 
difference between TTPs for respectively previous and 
current metronomic treatment (means 12.5 vs 17.1 weeks; 
Wilcoxon test, p=0.35).
Of particular interest, in 11 patients a decrease in pain 
and  antalgic  drug  administration  was  rapidly  observed 
after initiation of the metronomic treatment.
Most importantly, according to the National Cancer 
Institute Common Toxicity Criteria 3.0, with 24 grade-
III and only 4 grade-IV AEs, tolerability was acceptable. 
They  were  mainly  hematological  (83  %  of  toxicities 
and  75%  of  children).  Six  patients  did  not  display 
any grade III or IV toxicities. It may be worthwhile to 
note that 4 of the patients (those with prior high dose 
chemotherapy followed by hematologic peripheral stem 
cell transplantation) accounted for 50% of all the AEs. No 
alopecia was reported and in all children except 1 who 
previously  received  high-dose  chemotherapy,  normal 
hair  growth  was  noted.  No  grade  III  or  IV  nausea  or 
vomiting was observed. Details are given in table 2. No 
patients stopped their treatment as a result of toxicity. 
Vinblastine dosage had to be reduced by 30% in 3 patients 
because of peripheral neurotoxicity (1 patient) and severe 
hematological toxicity (2 patients). Celecoxib was stopped 
in 2 patients due to renal insufficiency in one case and 
hemoptysis (related to lung metastasis) in the other, and 
MTX dosage was reduced in 4 patients because of grade 
II or III mucositis.
Toxicity Number of episodes Number of patients
Grade III 24 10
Absolute neutrophil count (>500-1000 G/L) 6 4
Hemoglobin (6.5–8.0 g/dL) 4 3
Leukocytes (1,000–2,000 G/L) 7 5
Neuropathy 1 1
Mucositis 1 1
Renal  Insuffisiency 1 1
Platelets (10.000-50.000 G/L) 3 2
Grade IV 4
Absolute neutrophil count (>500-1000 G/L) 2 1
Platelets < 10.000 G/L 2 2
Table 2: Grade III/IV toxicities observed during the metronomic chemotherapy protocol.Oncotarget 2011; 2:  960 - 965 963 www.impactjournals.com/oncotarget
DISCUSSION
We report here the results of a 4-drug metronomic 
regimen in children with relapsing or refractory solid 
tumors.  Of  note,  the  treatment  was  also  proposed  to 
children at very high-risk of relapse, so that 3 patients 
received this treatment as a maintenance therapy (Table 
1). Interestingly, 2 out of these 3 patients received the 
treatment for almost a year. For one patient the treatment 
is still ongoing. The second patient relapsed 2 months 
after stopping maintenance suggesting it may have been 
stopped to early as previously reported in a patient with 
medulloblastoma  treated  with  the  COMBAT  regimen 
(22). 
Table 1:  Patients characteristics and treatment outcomes.
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1 M Medulloblastoma PD 5.5 16 3 yes yes etoposide 8 8 PD 17 DOD
2 M Rhabdoid Renal 
Tumor PD 12 23 3 no yes etoposide 6 13 PD 33 DOD
3 M Medulloblastoma  PD 9 22 3 no yes etoposide 8 14 PD 52 AWD
4 F Osteosarcoma M* 11.5 43 3 no no no 6 52 CR 68 AWD
5 M Neuroblastoma M 6 20 4 no yes COMBAT 6 8 PD 12 DOD
6 M Nephroblastoma M 12 46 4 yes yes no 5 14 PD 22 DOD
7 F Osteosarcoma M 16 40 3 no no no 25 6 PD 14 DOD
8 M RMS M** 20 54 2 no yes
nvb-
cyclo//tmz 16 52 CR 56 CR
9 F Osteosarcoma M*** 16 52 2 no no no 6 24 CR 72 AWD
10 M
Hodgkin 
Lymphoma  PD 18 45 4 yes**** yes no ? 20 PR 24 AWD
11 M Glioblastoma PD 9.5 44 3 no yes tmz 4 6 PD 6 DOD
12 F Medulloblastoma  PD 12 34 3 no yes etoposide 6 6 PD 16 DOD
13 F
Supratentorial
PNET PD 11 30 2 yes yes no 34 14 PD 27 AWD
14 M Medulloblastoma  PD 14 24 4 no yes no 32 6 PD 22 DOD
15 M Osteosarcoma PD 10 56 3 no no no 12 14 PD 30 DOD
16 M Osteosarcoma PD 8.5 27 1 no no no 84 24 PD 25 AWD
SD: Stable Disease; PD: Progressive Disease; AWD: Alive With Disease; DOD: Died Of Disease; M: Maintenance; Nvb: Navelbine; Tmz : Temozolomide; Cyclo: 
Cyclophosphamide; N.A : Non Available
°: this patient received zoledronic acid together with the metronomic regimen.
*:  this patient had a primary refractory metastatic osteosarcoma that progressed during the 2 first lines of chemotherapy. Metronomic chemotherapy was 
proposed as a maintenance therapy after obtaining surgical complete remission of both the primary tumour and bilateral lung metastasis. Monthly zoledronic acid 
was associated to the metronomic treatment.
** this patients had a third metastatic relapse of rhabdomyosarcoma. Metronomic maintenance was proposed after obtaining surgical CR and irradiation of the 
metastatic site.
*** this patient was proposed maintenance therapy after obtaining a 3rd surgical complete remission of a metastatic osteosarcoma. 
**** :this patient with Hodgkin lymphoma underwent both high dose chemotherapy followed by peripheral blood stem cell transplantation for a relapse and 
autologous bone marrow transplantation for a subsequent relapse.
¤The COMBAT protocol is a combination of metronomic etoposide, temzolomide, celecoxib and retinoic acid.
¤¤: patients with Li Fraumeni syndrom who developed an osteosarcoma as a third tumor.
In children, who received the protocol as maintenance therapy and who were in CR at treatment initiation, the best status was considered as stable disease.Oncotarget 2011; 2:  960 - 965 964 www.impactjournals.com/oncotarget
Treatment tolerance was similar to what has been 
reported with previous multi-drug metronomic regimens 
in pediatric populations [3, 4, 5, 10]. Mostly grade III/IV 
hematological toxicities were observed in 10 patients. It 
may be worthwhile to note that ¼ of the patients (those 
with prior high dose chemotherapy followed by peripheral 
hematopoietic stem cells transplantation) accounted for 
50% of all the AEs. Six out of 16 patients (37.5%) did 
not display any grade III or IV toxicities. Therefore, this 
regimen is well tolerated in children and also allows 
treatment of previously very heavily treated who may not 
have been able to tolerate further MTD chemotherapy.
The initial combination of celecoxib and low dose 
MTX  led  to  mucositis  in  2  out  of  the  3  first  treated 
patients.  Although  no  pharmacokinetics  study  was 
performed to confirm the deleterious interaction between 
these two drugs, and despite the fact that cox-2 inhibitors 
did not change low-dose MTX pharmacokinetics in adults 
[23], it was decided to lower the doses of MTX. After the 
decrease in MTX dosage, the tolerance of the regimen was 
indeed improved and no further mucositis were observed.
One radiological response was noted after 2 cycles 
in a patient with Hodgkin lymphoma and 4 disease 
stabilizations  were  observed,  according  to  classic 
WHO criteria. Although partial and complete responses 
have  been  reported  in  children  receiving  metronomic 
chemotherapy [3, 4, 5, 24], this type of therapy may 
more likely lead to tumor stabilizations [3, 4, 7, 10, 14]. 
In  this  regard  it  should  be  noted  that  the  RECIST  or 
WHO criteria may not be adapted in the evaluation of 
anti-angiogenic therapies [25]. Indeed, anti-angiogenic 
treatments are mainly considered as cytostatic, and as 
such are most likely to inhibit tumor progression rather 
than induce tumor regression. When considering the time 
to  progression  (TTP),  which  defines  a  clinical  benefit 
by comparing the TTP while the patient is receiving the 
therapy immediately before the treatment of interest versus 
the TTP while under the experimental treatment, we found 
that the experimental MC regimen was associated with 
a longer TTP in 8 patients as compared to the previous 
lines of treatment. Such analysis of TTP paves the way for 
new clinical trial design to evaluate the efficacy of non-
cytotoxic therapies such as metronomic treatments, which 
are less likely to produce tumor response assessed with 
RECIST.
Besides its potential effect in restraining tumor 
progression, MC seems to be able to help controlling 
pain in children with cancer. We previously reported fast 
improvement in pain control in children under MC [10] 
and  Kivivuori  et  al.  reported  that  MC  could  also  help 
controlling pain symptoms in children with inoperable 
brainstem gliomas [26]. In the present study, we reported 
similar findings  as  11  children (69%)  experienced less 
pain, thus leading to a decrease in antalgic treatment, 
confirming the potential interest of MC in the palliative 
setting as already well established with for instance oral 
etoposide.
Among  the  16  patients  who  were  treated  with 
this  metronomic  regimen,  7  had  previously  received 
MC, which mainly consisted in oral etoposide alone or 
combined with other metronomic agents. Interestingly, 
in these patients, TTP was equal or longer with the new 
metronomic  protocol  when  compared  to  TTP  with  the 
previous metronomic regimen. Furthermore, patients for 
whom previous metronomic treatment helped controlling 
their disease also seemed to have their disease stabilized 
for longer period with the 4-drug regimen tested here, 
suggesting that cross resistance between metronomic 
regimens may not be systematic, opening the way for 
potential  treatment  with  several  lines  of  MC  regimens 
and also re-challenge with the same treatment as recently 
reported by Sterba et al. [22]. 
Compliance is an important issue when considering 
oral treatments; we did not evaluate compliance in this 
study. Nevertheless, patients were always present for the 
planned dose of vinblastine injections suggesting a good 
adherence to treatment, although compliance with daily 
oral drugs and weekly injections are different type of 
constraints.
CONCLUSION
The 4-drug regimen we report in this study was well 
tolerated.  Although,  efficacy  cannot  be  fully  assessed 
due to the small number of patients who were treated, 
the  longer  TTP  observed  when  compared  to  previous 
lines of treatment strongly suggests a potential interest in 
children with refractory disease. A prospective national 
multicentric phase II study with ancillary biologic study is 
currently under way (clinicaltrial.gov - NCT01285817) as 
a result of this pilot study.
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